Denise Menezes Brunetta, Luany Elvira Mesquita Carvalho, Nathália Martins Beserra, Claudianne Maia de Farias Lima, Claudia Mota Leite Barbosa Monteiro, Lara Facundo de Alencar Araripe, Fernanda Luna Neri Benevides, Maria Isaaquielle Andrade de Oliveira, Anastácia Maria Viana Silva, Suzanna Araújo Tavares Barbosa, Eliane Ribeiro da Costa Oliveira, Davi Alves Cavalcante, Franklin Jose Candido Santos, Luciana Maria de Barros Carlos
{"title":"在中低收入国家成功实施病人血液管理计划。","authors":"Denise Menezes Brunetta, Luany Elvira Mesquita Carvalho, Nathália Martins Beserra, Claudianne Maia de Farias Lima, Claudia Mota Leite Barbosa Monteiro, Lara Facundo de Alencar Araripe, Fernanda Luna Neri Benevides, Maria Isaaquielle Andrade de Oliveira, Anastácia Maria Viana Silva, Suzanna Araújo Tavares Barbosa, Eliane Ribeiro da Costa Oliveira, Davi Alves Cavalcante, Franklin Jose Candido Santos, Luciana Maria de Barros Carlos","doi":"10.1111/vox.13772","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Transfusions are common, but their use is decreasing in some countries as a result of increased risk awareness and the implementation of patient blood management (PBM), an evidence-based approach to optimize patient outcomes. This study aimed to detail the implementation of PBM in a Brazilian state and its impact on transfusion rates and associated costs.</p><p><strong>Materials and methods: </strong>The PBM implementation involved several strategies: medical education, haematology consultation services, provision of intravenous iron and other medications, establishment of PBM and perioperative anaemia clinics, cell salvage and acute normovolaemic haemodilution, anaemia reference laboratories and rotational thromboelastometry. The program's implementation was assessed through quality indicators and cost analysis.</p><p><strong>Results: </strong>Since 2016, there have been reductions in transfusion rates, mainly in red blood cell (RBC) transfusion. Quality indicators showed an increase in single-RBC transfusions from 53% in December 2015 to 85.9% in June 2024 and a decrease in transfusions for patients with Hb ≥7 g/dL from 5.9% in March 2021 to 2.7% in May 2024. The PBM programme led to an estimated annual cost saving of R$2.63 million (US $487,000), if considered RBC direct costs, and from R$9.69 million to R$16.145 million (US $1.79-$2.99 million) in activity-based costs, considering only the reduction in RBC transfusions.</p><p><strong>Conclusion: </strong>The PBM programme in Ceará successfully reduced transfusion rates and associated costs through a multidisciplinary approach, medical education and government support. This model demonstrates the potential for significant healthcare improvements and cost savings and can serve as a benchmark for other regions and countries, especially in low- and middle-income settings.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful implementation of a patient blood management programme in a lower middle-income state.\",\"authors\":\"Denise Menezes Brunetta, Luany Elvira Mesquita Carvalho, Nathália Martins Beserra, Claudianne Maia de Farias Lima, Claudia Mota Leite Barbosa Monteiro, Lara Facundo de Alencar Araripe, Fernanda Luna Neri Benevides, Maria Isaaquielle Andrade de Oliveira, Anastácia Maria Viana Silva, Suzanna Araújo Tavares Barbosa, Eliane Ribeiro da Costa Oliveira, Davi Alves Cavalcante, Franklin Jose Candido Santos, Luciana Maria de Barros Carlos\",\"doi\":\"10.1111/vox.13772\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Transfusions are common, but their use is decreasing in some countries as a result of increased risk awareness and the implementation of patient blood management (PBM), an evidence-based approach to optimize patient outcomes. This study aimed to detail the implementation of PBM in a Brazilian state and its impact on transfusion rates and associated costs.</p><p><strong>Materials and methods: </strong>The PBM implementation involved several strategies: medical education, haematology consultation services, provision of intravenous iron and other medications, establishment of PBM and perioperative anaemia clinics, cell salvage and acute normovolaemic haemodilution, anaemia reference laboratories and rotational thromboelastometry. The program's implementation was assessed through quality indicators and cost analysis.</p><p><strong>Results: </strong>Since 2016, there have been reductions in transfusion rates, mainly in red blood cell (RBC) transfusion. Quality indicators showed an increase in single-RBC transfusions from 53% in December 2015 to 85.9% in June 2024 and a decrease in transfusions for patients with Hb ≥7 g/dL from 5.9% in March 2021 to 2.7% in May 2024. The PBM programme led to an estimated annual cost saving of R$2.63 million (US $487,000), if considered RBC direct costs, and from R$9.69 million to R$16.145 million (US $1.79-$2.99 million) in activity-based costs, considering only the reduction in RBC transfusions.</p><p><strong>Conclusion: </strong>The PBM programme in Ceará successfully reduced transfusion rates and associated costs through a multidisciplinary approach, medical education and government support. This model demonstrates the potential for significant healthcare improvements and cost savings and can serve as a benchmark for other regions and countries, especially in low- and middle-income settings.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.13772\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.13772","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Successful implementation of a patient blood management programme in a lower middle-income state.
Background and objectives: Transfusions are common, but their use is decreasing in some countries as a result of increased risk awareness and the implementation of patient blood management (PBM), an evidence-based approach to optimize patient outcomes. This study aimed to detail the implementation of PBM in a Brazilian state and its impact on transfusion rates and associated costs.
Materials and methods: The PBM implementation involved several strategies: medical education, haematology consultation services, provision of intravenous iron and other medications, establishment of PBM and perioperative anaemia clinics, cell salvage and acute normovolaemic haemodilution, anaemia reference laboratories and rotational thromboelastometry. The program's implementation was assessed through quality indicators and cost analysis.
Results: Since 2016, there have been reductions in transfusion rates, mainly in red blood cell (RBC) transfusion. Quality indicators showed an increase in single-RBC transfusions from 53% in December 2015 to 85.9% in June 2024 and a decrease in transfusions for patients with Hb ≥7 g/dL from 5.9% in March 2021 to 2.7% in May 2024. The PBM programme led to an estimated annual cost saving of R$2.63 million (US $487,000), if considered RBC direct costs, and from R$9.69 million to R$16.145 million (US $1.79-$2.99 million) in activity-based costs, considering only the reduction in RBC transfusions.
Conclusion: The PBM programme in Ceará successfully reduced transfusion rates and associated costs through a multidisciplinary approach, medical education and government support. This model demonstrates the potential for significant healthcare improvements and cost savings and can serve as a benchmark for other regions and countries, especially in low- and middle-income settings.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.